# US 2015/0147338 A1 · Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147338 A1
- Document ID: US20150147338A1
- Status: Published application
- Kind: A1
- Application number: 14/405,280
- Filed: 2013-06-06
- Published: 2015-05-28
- Earliest claimed: 2012-06-06
- Assignees: Galectin Therapeutics, Inc.
- Applicants: Galectin Therapeutics, Inc.
- Inventors: Peter G. Traber; Eliezer Zomer; Anatole A. Klyosov
- Web page: https://patentgrep.com/patent/US20150147338A1

## CPC

- A61K 31/738: Cross-linked polysaccharides
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.

## Claims

### Claim 1

(canceled)

### Claim 2

A method comprising the steps of:
obtaining a composition for parenteral or enteral administration comprising a galacto-rhamnogalacturonate in an acceptable pharmaceutical carrier wherein the galacto-rhamnogalacturonate is a galactoarabino-rhamnogalacturonate, comprising a 1,4-linked galacturonic acid (GalA) and methyl galacturonate (MeGalA) residues backbone linked to branched heteropolymers of alternating oligomers of α-1,2 linked rhamnose and α-1,4-linked GalA residues, the rhamnose residues carrying a primary branching of oligomers of 1,4-β-D-galactose residues, 1,5-α-L-arabinose residues, or combinations thereof;
administering to a subject in need thereof an effective dose of the composition that results in at least one of the following:
reduction of at least 10% of the expression of iNOS in a disease affected tissue wherein the subject has at a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.

### Claim 3 (depends on 2)

The method of claim 2 wherein the 1,4-β-D-galactose and 1,5-α-L-arabinose residues are present in a 2:1 to a 3:1 ratio.

### Claim 4 (depends on 2)

The method of claim 2 wherein the 1,4-β-D-galactose residues, the 1,5-α-L-arabinose residues or combination thereof represent at least 10 molar percent of the total molar carbohydrates.

### Claim 5

(canceled)

### Claim 6 (depends on 2)

The method of claim 2 wherein the galacto-rhamnogalacturonate has an average molecular weight ranging from 5 kDa to 55 kDa.

### Claim 7 (depends on 2)

The method of claim 2 wherein the galacto-rhamnogalacturonate has an average molecular weight ranging from 2 kDa to 80 kDa.

### Claim 8 (depends on 2)

The method of claim 2 wherein the galacto-rhamnogalacturonate has an average molecular weight ranging from 20 kDa to 70 kDa.

### Claim 9 (depends on 2)

The method of claim 2 wherein the galacto-rhamnogalacturonate has an average molecular weight ranging from 2 kDa to 65 kDA.

### Claim 10 (depends on 2)

The method of claim 2 wherein the galacto-rhamnogalacturonate has an average molecular weight ranging from 45 kDa to 65 kDA.

### Claim 11 (depends on 2)

The method of claim 2 wherein the galacto-rhamnogalacturonate has an average molecular weight ranging from 2 kDa to 20 kDa.

### Claim 12 (depends on 2)

The method of claim 2 wherein when the galacto-rhamnogalacturonan compound is utilized in an assay to treat monocytes or macrophages stressed with endotoxin, the assay results in the reduction of TNF-alpha cytokine from the activated monocytes or the macrophages.

### Claim 13 (depends on 12)

The method of claim 12 wherein the galacto-rhamnogalacturonan compound is capable of reducing the secretion of TNF alpha by the activated monocytes or the activated macrophages by at least 25%.

### Claim 14 (depends on 2)

The method of claim 2 wherein when the galacto-rhamnogalacturonan compound is utilized to treat LX2 immortalized human hepatic stellate cells in a cell viability assay, the assay treatment results in substantially no decreased viability of activated hepatic stellate cells following administration of the galacto-rhamnogalacturonan compound.

### Claim 15 (depends on 2)

The method of claim 2 wherein in the step of administering the galacto-rhamnogalacturonate is co-administered with effective amount of a therapeutic agent.

### Claim 16 (depends on 15)

The method of claim 15 wherein the therapeutic agent is one of cysteamine or a pharmaceutically acceptable salt thereof, cystamine or a pharmaceutically acceptable salt thereof, an anti-oxidant compound, lecithin, vitamin B complex, a bile salt preparations, an antagonists of Cannabinoid-1 (CB1) receptor, an inverse agonists of Cannabinoid-1 (CB1) receptor, a peroxisome proliferator-activated receptor) activity regulators, a benzothiazepine or benzothiepine compound, an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU, a heteroatom-linked substituted piperidine and derivatives thereof, an azacyclopentane derivative, acylamide compound having secretagogue or inducer activity of adiponectin, a quaternary ammonium compound, Glatiramer acetate, pentraxin proteins, a HMG-CoA reductase inhibitor, n-acetyl cysteine, isoflavone compound, a macrolide antibiotic, a galectin inhibitor, an antibody, or any combination of the foregoing.

### Claim 17 (depends on 16)

The method of claim 16 wherein the anti-oxidant compound comprises a water soluble Vitamin E preparation, mixed carotenoids, selenium or combinations thereof.

### Claim 18 (depends on 16)

The method of claim 16 wherein the bile salt preparation comprises ursodeoxycholic acid, chenodeoxycholic acid of naturally occurring bile acids or bile acid salts, chenodeoxycholic acid of synthetic bile acids or bile acid salts or combinations thereof.

### Claim 19

(canceled)

### Claim 20 (depends on 16)

The method of claim 16 wherein the HMG-CoA reductase inhibitors comprises atorvastatin, simvastatin or combinations thereof.

### Claim 21 (depends on 16)

The method of claim 16 wherein the galectin inhibitor comprises small organic inhibitors of galectin, monoclonal antibodies, RNA inhibitors, small binding peptides, protein inhibitors or combinations thereof.

### Claim 22 (depends on 16)

The method of claim 16 wherein the antibody is an antibody against lysyl oxidase or an antibody against connective tissue growth factor.

### Claim 23

(canceled)

### Claim 24

Use of a galacto-rhamnogalacturonate compound in the manufacture of a pharmaceutical composition for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases, wherein the galacto-rhamnogalacturonate is a galactoarabino-rhamnogalacturonate, comprising a 1,4-linked galacturonic acid (GalA) and methyl galacturonate (MeGalA) residues backbone linked to branched heteropolymers of alternating oligomers of α-1,2 linked rhamnose and α-1,4-linked GalA residues, the rhamnose residues carrying a primary branching of oligomers of 1,4-β-D-galactose residues, 1,5-α-L-arabinose residues, or combinations thereof.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

An admixture having a galacto-rhamnogalacturonate and a therapeutic agent for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases, wherein the galacto-rhamnogalacturonate is a galactoarabino-rhamnogalacturonate, comprising a 1,4-linked galacturonic acid (GalA) and methyl galacturonate (MeGalA) residues backbone linked to branched heteropolymers of alternating oligomers of α-1,2 linked rhamnose and α-1,4-linked GalA residues, the rhamnose residues carrying a primary branching of oligomers of 1,4-β-D-galactose residues, 1,5-α-L-arabinose residues, or combinations thereof.

### Claim 35 (depends on 34)

The admixture of claim 34 wherein the therapeutic agent is one of cysteamine or a pharmaceutically acceptable salt thereof, cystamine or a pharmaceutically acceptable salt thereof, an anti-oxidant compound, lecithin, vitamin B complex, a bile salt preparations, an antagonists of Cannabinoid-1 (CB1) receptor, an inverse agonists of Cannabinoid-1 (CB1) receptor, a peroxisome proliferator-activated receptor) activity regulators, a benzothiazepine or benzothiepine compound, an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU, a heteroatom-linked substituted piperidine and derivatives thereof, an azacyclopentane derivative, acylamide compound having secretagogue or inducer activity of adiponectin, a quaternary ammonium compound, Glatiramer acetate, pentraxin proteins, a HMG-CoA reductase inhibitor, n-acetyl cysteine, isoflavone compound, a macrolide antibiotic, a galectin inhibitor, an antibody, or any combination of the foregoing.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)
